Glaxo, Valentis expand GeneSwitch technology license

Valentis Inc said it expanded its April 2001 license agreement with GlaxoSmithKline PLC to enable GlaxoSmithKline to use its GeneSwitch gene regulation technology for research purposes for up to 10 years.

Glaxo, Valentis expand GeneSwitch technology license

Valentis Inc said it expanded its April 2001 license agreement with GlaxoSmithKline PLC to enable GlaxoSmithKline to use its GeneSwitch gene regulation technology for research purposes for up to 10 years.

Valentis will receive €1.1m under the expanded agreement.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

CONNECT WITH US TODAY

Be the first to know the latest news and updates

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited